[The efficacy of subcutaneous sumatriptan for the treatment of migraine attack].
Sumatriptan is a novel drug for the treatment of acute migraine attacks. The aim of this study was to assess the efficacy of a 6 mg s.c. Sumatriptan in the early acute treatment of migraine. Patients were recruited with a current history of migraine with and without aura. 58 patients treated 1 migraine attacks at home using an autoinjector with a dose 6 mg of sumatriptan. Patient assessed headache severity and other migraine symptoms 1 and 4 h after treatment. 55% patients reported headache relief after 1 h and 77% patients after 4 h. Adverse events were reported by 11% of patients. In conclusion, sumatriptan were effective and well tolerated in the acute treatment of migraine.
Stepień
A
A
Kliniki Neurologicznej Wojskowego Instytutu Medycyny Lotniczej w Warszawie.
D000208:Acute Disease; D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D018170:Sumatriptan / Q000627:therapeutic use*; D013997:Time Factors
D017366:Serotonin Receptor Agonists; D018170:Sumatriptan